Clinical

Dataset Information

0

Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal cancer


ABSTRACT: Interventions: Irinotecan plus S-1 with cetuximab combination therapy Cetuximab 400mg/m2 day1 and then 250mg/m2 day 8,15,22 weekly until PD, or Cetuximab 500mg/m2 day 1, 15, 29 biweekly until PD Irinotecan 100 mg/m2 day1,15, 30 biweekly until PD S-1 S-1 80mg [BSA<1.25m2] or 100mg [1.25m2

DISEASE(S): Advanced/metastatic Colorectal Cancer

PROVIDER: 2620325 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2622245 | ecrin-mdr-crc
| 2619853 | ecrin-mdr-crc
| 2620142 | ecrin-mdr-crc
| 2620657 | ecrin-mdr-crc
| 2643378 | ecrin-mdr-crc
| 2626017 | ecrin-mdr-crc
| 2621834 | ecrin-mdr-crc
| 2627635 | ecrin-mdr-crc
| 2623200 | ecrin-mdr-crc
| 2618840 | ecrin-mdr-crc